Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)

Status Active, not recruiting

Clinical Trial Summary

This project concerns a population at risk of sudden death by dissection of the thoracic aorta. Its interest is to make it possible to recognize the genes that protect or worsen the evolution of aneurysms, to better understand the mechanisms involved, to detect and treat aneurysms of the thoracic aorta, wich is a pathology that is completely silent clinically until life-threatening complications. The variability in the severity of the disease within the same family is related to modifier genes. The objective is to find the modifying factors that account for the variability in the severity of the progression of aneurysms of the thoracic aorta.

Clinical Trial Description

Thoracic aortic aneurysms are silent, asymptomatic, potentially fatal pathologies due to the risk of aortic dissection. More and more often they are found during imaging tests done for another reason. Some aneurysms have genetic origin (autosomal dominantly inherited) and are particularly interesting because they can be recognized early (due to possible family screening), which allows us to understand the natural history of this pathology. The discovery of genes whose mutations explain the occurrence of these family aneurysms (initiator gene) has also made it possible to improve family screening and to better understand the pathophysiology of these aneurysms: we now recognize 3 groups of genes involved (extracellular matrix, contractile proteins of smooth muscle cell, TGF-β pathway (Transforming Growth Factor) [including mutations in TGF-β receptor 2 gene, TGFBR2]). The variability in the severity of signs and aortic involvement is particularly marked in patients with aortic aneurysms due to mutations in the TGFBR2 gene. Some patients with these mutations present aggressive aneurysms with early dissection. Other patients have isolated late-onset aneurysms, and others have no signs. This variability generates problems for clinical practice to give appropriate genetic advice, but also to adapt imaging monitoring, therapy, or sports restriction. The present protocol aims is to investigate the variability in the severity of the disease within a large family carrying a mutation in the TGFBR2 gene. The MFS1 family is a family in which the aortic pathology is due to a mutation in the TGFBR2 gene. All patients with this family carry the same TGFBR2 mutation, heterozygous. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05146375
Study type	Observational
Source	French Cardiology Society
Contact
Status	Active, not recruiting
Phase
Start date	November 24, 2022
Completion date	November 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01390181` - The Effect of Losartan in Bicuspid Aortic Valve Patients	N/A
Recruiting	`NCT00339053` - Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair	Phase 4
Not yet recruiting	`NCT05395598` - Incidence of Major Complication in Case of Thoracic Aortic Aneurysm
Recruiting	`NCT00549315` - Clinical Study of Thoracic Aortic Aneurysm Exclusion	N/A
Recruiting	`NCT05777460` - Mid- and Long-term Outcomes of Custom-made Aortic Devices
Completed	`NCT01082172` - South American Thoracic Stent-Graft Study	N/A
Recruiting	`NCT03824626` - Biomechanical Reappraisal of Planning for Thoracic Endovascular Aortic Repair
Completed	`NCT04663074` - Intravascular Ultrasound (IVUS) in Complex Aortic Endovascular Interventions
Recruiting	`NCT04747626` - B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair	N/A
Active, not recruiting	`NCT05143138` - Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
Completed	`NCT00111176` - STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft	N/A
Recruiting	`NCT05639400` - Thoraflex Hybrid and Relay Extension Post-Approval Study
Terminated	`NCT02735720` - The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study
Completed	`NCT02256163` - Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm	N/A
Recruiting	`NCT06377033` - Using the EHR to Advance Genomic Medicine Across a Diverse Health System	N/A
Recruiting	`NCT06094127` - Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
Recruiting	`NCT03998631` - Comparison of Carbon Dioxide and Saline Flush to Saline Flush in TEVAR and TAVI Procedures to Reduce Cerebral Ischemia	Phase 1
Completed	`NCT05414318` - CTAG Dissection/Trauma Post Marketing Surveillance Japan
Completed	`NCT04756778` - Indexed Aortic Area in Bicuspid Aortic Valve Aortopathy
Withdrawn	`NCT04197648` - Effects of Exercise on Thoracic Aneurysms	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2) — MSF1-TGFBR2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms